Gainers

Immutep, Inc. IMMP shares increased by 65.45% to $1.82 during Wednesday's pre-market session.

RTI Surgical Hldgs, Inc. RTIX shares increased by 20.35% to $4.08.

Acorda Therapeutics, Inc. ACOR shares moved upwards by 18.57% to $0.83. The most recent rating by H.C. Wainwright, on May 6, is at Neutral, with a price target of $5.

Moderna, Inc. MRNA shares increased by 16.87% to $87.70. The most recent rating by Brookline Capital, on Jul 13, is at Buy, with a price target of $95.

TherapeuticsMD, Inc. TXMD stock moved upwards by 16.10% to $1.73. According to the most recent rating by JP Morgan, on May 19, the current rating is at Neutral.

VBI Vaccines, Inc. VBIV stock moved upwards by 14.85% to $5.18.

Novan, Inc. NOVN shares rose 10.80% to $0.56.

Fluidigm, Inc. FLDM stock increased by 9.42% to $5.92.

Orchard Therapeutics, Inc. ORTX stock moved upwards by 9.37% to $5.60.

ReWalk Robotics, Inc. RWLK shares increased by 8.40% to $1.29.

 

Losers

Zynex, Inc. ZYXI stock decreased by 11.14% to $23.30 during Wednesday's pre-market session. According to the most recent rating by B. Riley FBR, on Jul 13, the current rating is at Neutral.

Endologix, Inc. ELGX stock declined 10.73% to $0.26. According to the most recent rating by BTIG, on May 12, the current rating is at Neutral.

IMV, Inc. IMV stock declined 8.86% to $4.22. The most recent rating by Wells Fargo, on May 18, is at Overweight, with a price target of $8.

Cleveland BioLabs, Inc. CBLI stock fell 8.26% to $3.

Myos Rens Technology, Inc. MYOS stock fell 7.76% to $1.19.

Dynatronics, Inc. DYNT stock declined 6.69% to $0.77. The most recent rating by Aegis Capital, on May 19, is at Buy, with a price target of $1.

Rigel Pharmaceuticals, Inc. RIGL stock declined 6.67% to $3.85. The most recent rating by JP Morgan, on May 27, is at Overweight, with a price target of $6.

Dare Bioscience, Inc. DARE shares fell 6.58% to $1.42. The most recent rating by Brookline Capital, on Apr 28, is at Buy, with a price target of $8.

Vaxart, Inc. VXRT shares declined 5.13% to $16.10. The most recent rating by B. Riley FBR, on Jul 13, is at Buy, with a price target of $22.

INmune Bio, Inc. INMB shares declined 5.08% to $14.95. The most recent rating by HC Wainwright & Co., on Jul 15, is at Buy, with a price target of $20.

Market News and Data brought to you by Benzinga APIs

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!